IC-2 Suppresses Proliferation and Induces Apoptosis of Bladder Cancer Cells via the Wnt/β-Catenin Pathway

AB Lingfeng Wu*
CD Shunliang He*
BC Yi He
BD Xueping Wang
ABCG Linfeng Lu

* Lingfeng Wu and Shunliang He contributed equally to this work

Corresponding Author: Linfeng Lu, e-mail: lulinfeng1898@126.com
Source of support: The work was supported by the Zhejiang Medical Science and Technology Project (grant no. 2016BY28003) and the Key Subject of Jiaxing Medicine (Urology, grant no. 04-F-18)

Background: The Wnt/β-catenin signaling pathway participates in many important tumorigeneses processes, including bladder cancer. The inhibition of abnormal activation of Wnt pathways might provide a new approach to tumor treatment. In the present study, we investigated the role of IC-2, a novel Wnt pathways small molecular inhibitor, in bladder cancer tumorigenesis.

Material/Methods: Bladder cancer cells were treated with various concentrations of IC-2 (0–5 μM) in vitro. The proliferation ability was measured using colony formation assay and apoptosis was measured using flow cytometry analysis. The protein expression was detected using Western blot analysis. Xenograft in vivo assay was performed to assess tumor growth.

Results: IC-2 suppressed the proliferation and aggravated the apoptosis of bladder cancer cells in dose-dependent and time-dependent manners in vitro. Moreover, high concentrations of IC-2 inhibited the Wnt pathway-related protein expression levels, including β-catenin, Cyclin D1, and TCF4. In vivo, administration of IC-2 in xenograft mice decreased the β-catenin expression and reduced the tumor volume.

Conclusions: Our results validate the tumor-inhibition effect of IC-2 on bladder cancer in vivo and in vitro, providing a novel therapeutic strategy for bladder cancer.

MeSH Keywords: beta Catenin • Small Molecule Libraries • Urinary Bladder Diseases

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/910742
**Background**

Bladder cancer is one of the most common malignant tumors and is the ninth most common malignancy worldwide [1,2]. Thousands of bladder cancer patients are diagnosed in developed countries and in developing countries every year [3]. Although treatment of bladder cancer is improving with technological advances, the overall survival times of bladder cancer patients are still poor, with a 5-year survival rate of about 50% [4]. With deeper understanding of bladder cancer pathology, increasing numbers of molecular pathways are being discovered and reported, revealing the pathogenetic mechanism of bladder cancer and aiding more effective diagnosis [5].

The Wnt/β-catenin signal transduction pathway is involved in many important biological events [6]. In the normal human body environment, the Wnt signal transduction pathway is highly conserved and not activated [7,8]. Abnormal activation of Wnt pathways plays an important role in the occurrence and development of tumors; therefore, the inhibition or blockage of the abnormal activation of Wnt pathways might provide a new approach to developing antineoplastic drugs, and Wnt pathways inhibitors may also be relevant in developing new cancer drugs [9]. Abnormal activation of the Wnt/β-catenin signaling pathway is one of the main causes of many kinds of tumors, including gastrointestinal carcinoma, glioma, and other cancers [10,11].

Existing articles have illustrated its exact role in tumorigenesis, as well as bladder cancer. In the present study, we investigated and validated the function of the novel small molecular inhibitor targeting Wnt pathway in bladder cancer cells, suggesting the valuable inhibition of bladder cancer tumorigenesis.

**Material and Methods**

**Bladder cancer cell lines and culture**

Bladder cancer cell lines (SW780, T24, UMUC3) and SV-40-immortalized human uroepithelial cell line (SV-HUC-1) were purchased from the Institute of Cell Research, Chinese Academy of Sciences (Shanghai, China) for use in this study. The cells were cultured in RPMI-1640 Medium (Invitrogen, Carlsbad, CA, USA) with 10% fetal bovine serum (FBS, Gibco, NY, USA). Plates were then placed in a 37°C incubator with a humidified atmosphere of 5% CO₂.

**Cell proliferation assay**

Cell proliferation was evaluated using the Cell Counting Kit-8 (CCK-8, Beyotime Inst Biotech, Shanghai, China) assay and colony formation assay according to the manufacturer's instructions. Briefly, for CCK-8 assay, bladder cancer cells (5x10³ per well) were seeded in a 96-well plate and incubated for 24 h, then the absorbance was measured at 450 nm using a microplate reader.

**Colonies formation assays**

Bladder cancer cells (1x10³ per well) were treated with IC-2 (0–5 μM) and seeded into 6-well plates supplemented complete growth medium (2 ml). After 1 week, the cells were fixed with 4% paraformaldehyde for 30 min and stained with 0.1% crystal violet (Beyotime, Shanghai, China) for 30 min. Colonies larger than 0.3 mm were counted. Final data were calculated from at least 3 independent experiments.

**Flow cytometry of apoptosis assay**

After being treated with IC-2 (0–5 μM) and fixed with 10 ml cold ethanol overnight, T24 cells were washed in PBS and treated with 500 μl PI/RNase Staining Solution (Invitrogen, Carlsbad, CA, USA) containing DNase-free RNase and reagent for 30 min at 37°C. After incubation, the cells were washed and analyzed immediately by flow cytometry analysis using a Beckman-Coulter CyAN ADP Analyzer (Beckman, CA, USA). Data were analyzed with FlowJo Version 6.1 software (TreeStar, USA). Final data were calculated from at least 3 independent experiments.

**Western blot assay**

Bladder cancer cells were lysed using protein extraction reagent radio-immunoprecipitation assay (RIPA) (Beyotime, Shanghai, China) with protease inhibitors cocktail and phenylmethanesulfonyl fluoride (PMSF) (Roche, Switzerland). Then, the protein was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes. The membrane was blocked with 5% non-fat milk and incubated with primary antibodies at 4°C overnight. Primary antibodies were β-catenin (1: 1000, Abcam), Cyclin D1 (1: 1000, Abcam), and TCF4 (1: 1000, Abcam). After that, the blots were incubated with goat anti-rabbit secondary antibody (Abcam, Cambridge, MA, USA). Enhanced chemiluminescence (ECL) chromogenic substrate was used to visualize the bands. GAPDH acted as the internal control.

**Immunofluorescence**

For immunofluorescence studies, T24 cells (4x10³ cells per well) were cultured in a 12-well culture dish and then treated with IC-2 (0 or 2 μM) for 72 h. Then, cells were fixed with paraformaldehyde (4%, 10 min), permeabilized in Triton X-100 (0.1%, 15 min), and washed using PBS. After being blocked in BSA (3%, 1 h) at room temperature, cells were incubated with anti-β-catenin antibody (1: 200) for 1 h at 37°C and then incubated
with fluorescein-labeled secondary antibody (1: 2000) for 1 h at room temperature. Then, cells were stained using nuclear staining with DAPI (Invitrogen) solution for 20 min. Lastly, cells were scanned and photographed using a Zeiss LSM510 Meta-confocal microscope.

**Xenograft tumor model**

BALB/c mice (4 weeks old) were purchased from the Institute of Laboratory Animal Sciences, Peking Union Medical College (Beijing, China). Animals were kept under specific pathogen-free conditions. T24 cells (3×10^6 per 100 μl) and IC-2 (0 or 5 mg/kg) were subcutaneously injected into the back of nude mice. All tumor volumes of mice were measured every 5 days. The tumor tissue was harvested after mice were sacrificed for further Western blot analysis and immunohistochemistry staining.

**Immunohistochemistry**

Neoplasm tissues excised from BALB/c mice were fixed in 10% formalin and embedded in paraffin. Briefly, after deparaffinization and rehydration using Dulbecco’s phosphate-buffered saline, tissue samples were cut into 10-μm-thick sections. Then, sections were incubated overnight with anti-β-catenin antibody (dilution 1: 200; Santa Cruz) and conjugated with corresponding secondary antibody. The antigens were visualized using a SP Rabbit & Mouse HRP kit (Kangwei, Beijing, China) according to the manufacturer’s instructions. Lastly, the sections were lightly counterstained with hematoxylin. The quantification and histogram analysis of immunostained images was done under a fluorescence microscope (Axiophot; Carl Zeiss, Jena, Germany).

**Statistical**

All data are displayed as mean ± standard deviation (SD) and generated from 3 independent experiments. The values of results were analyzed using the t test or χ^2 test using SPSS version 19.0 software (SPSS Inc. Chicago, IL, USA) and presented using GraphPad Prism 6 software (GraphPad Software Inc., La Jolla, CA, USA). P values of less than 0.05 were considered to be statistically significant.

**Results**

**IC-2 inhibited bladder cancer cells proliferation and aggravated the apoptosis in a dose-dependent manner**

To test the biologic role of IC-2 on bladder cancer cells, a series of experiments were performed. Bladder cancer cell lines SW780, T24, and MUC3 and control normal cell line SV-HUC-1 were treated with different concentrations of IC-2 (0–5 μM). After being treated with IC-2, the relative survival rate of bladder cancer cells showed that high concentration (5 μM) of IC-2 significantly decreased the survival of cells, especially in T24 cells (Figure 1A). T24 cells were chosen as the target for further research. CCK-8 assay showed that the proliferation ability was downregulated in time-dependent and dose-dependent manners (Figure 1B). Colony formation assay showed that the higher concentration of IC-2 significantly decreased the number of colonies compared with the low concentration (Figure 1C, 1D). Flow cytometry showed that the higher concentration of IC-2 promoted the apoptosis of T24 cells compared with the low concentration (Figure 1E, 1F). Overall, results showed that IC-2 inhibited bladder cancer cells proliferation and aggravated the apoptosis in a dose-dependent manner.

**IC-2 inhibited activation of the Wnt/β-catenin pathway in bladder cancer cells**

Activation of the Wnt/β-catenin pathway and the accumulation of β-catenin are critical processes in tumorigenesis. Thus, we proposed that IC-2, acting as a small molecular inhibitor targeting the Wnt/β-catenin pathway, would depress activation of the Wnt pathway in tumor cells. We measured the Wnt/β-catenin pathway-related protein expression in T24 cells using Western blot analysis. Results showed that protein expression levels of β-catenin, Cyclin D1, and TCF4 were decreased by treatment with a high concentration of IC-2 (2 μM) (Figure 2A–2C). Moreover, immunofluorescence assay showed that the location of β-catenin moved to cytoplasm from nuclei (Figure 2D). Our results revealed that the high concentration of IC-2 inhibited activation of the Wnt/β-catenin pathway in bladder cancer cells.

**IC-2 inhibited bladder cancer cells xenograft tumor growth and decreased the β-catenin expression in vivo**

To test the biologic role of IC-2 on bladder cancer tumor growth, assay of xenograft mice was performed by subcutaneously transplanting T24 cells into BALB/c nude mice. Results showed that the bioluminescent intensity in tumors treated with IC-2 (5 mg/kg) was significantly lower than that of the control group (Figure 3A, 3B). Expression of β-catenin protein was decreased in mice treated with IC-2 (5 mg/kg) (Figure 3C). The tumor volumes in the group administered IC-2 (5 mg/kg) were lower than in the control group (Figure 3D). Immunohistochemistry assay showed that the stained β-catenin was decreased in the IC-2 (5 mg/kg) group compared to the control group (Figure 3E). In summary, results showed that IC-2 inhibited bladder cancer cells xenograft tumor growth in vivo and decreased the β-catenin expression.
Figure 1. IC-2 inhibited bladder cancer cells proliferation and aggravated the apoptosis dose-dependently. (A) The relative survival rate of bladder cancer cell lines (SW780, T24, and UMUC3) and control normal cell line (SV-HUC-1) treated with different concentrations of IC-2 (0–5 μM). (B) CCK-8 assay showed the proliferation ability of bladder cancer cells in time-dependent and dose-dependent manners. (C, D) Colony formation assay showed the colonies numbers. (E, F) Flow cytometry showed the apoptosis of T24 cells. Data are presented as mean ±SD. * P<0.05, ** P<0.01 indicates a significant difference.
**Figure 2.** IC-2 inhibited the activation of Wnt/β-catenin pathway in bladder cancer cells. (A) The expression of β-catenin protein in T24 cells treated with IC-2 (0, 2 μM). (B) The expression of Cyclin D1 protein. (C) The expression of TCF4 protein. (D) Immunofluorescence assay of β-catenin showed the location in cytoplasm and nuclei. Data are presented as mean ±SD. **P<0.01 indicates a significant difference.

**Figure 3.** IC-2 inhibited bladder cancer cells xenograft tumor growth and decreased the β-catenin expression in vivo. (A, B) Bioluminescent imaging and bioluminescent intensity in BALB/c nude mice treated with IC-2 (5 mg/kg) and blank control. (C) Expression of β-catenin protein in mice treated with blank control and IC-2 (5 mg/kg). (D) Tumor volumes in the IC-2 (5 mg/kg) group and control group measured every 5 days. (E) Immunohistochemistry assay showed the stained β-catenin. Data are presented as mean ±SD. *P<0.05, **P<0.01 indicates a significant difference.
Discussion

The Wnt/β-catenin signaling pathway, consisting of canonical and non-canonical branches, plays important roles in multiple pathological process and tumorigenesis [12–14]. Emerging evidence indicates that inhibition of the Wnt/β-catenin signaling pathway contributes to the treatment and prevention of cancers, including bladder cancer [15,16]. In the present study, we investigated the biological role of a novel small molecular inhibitor targeting Wnt signaling pathways, IC-2, on bladder cancer cells. Tumorous characteristics and explored the potential therapeutic strategy for bladder cancer.

Small molecular inhibitor targeting Wnt signaling pathways are a category of novel inhibitors that can specifically integrate with β-catenin and decrease the concentration [17,18]. The abundance and nuclear location of β-catenin are critical in Wnt signaling pathways activation [19]. The persistent existence of TCF-β-catenin complex in nuclei is a common feature of cancer [20]. IC-2, a derivative of ICG-001, is a novel identified small molecular inhibitor targeting Wnt signaling pathway [21]. Using TOP/FOP flash report gene screening, we showed that from the small molecular inhibitor library, IC-2 had the most significant inhibitory effect on the Wnt signaling pathway.

The vital role of the Wnt/β-catenin pathway in bladder cancer progression has been adequately explored and reported [22]. Using in vitro functional experiments, we performed a series of validation assays to explore the effect of IC-2 on bladder cancer cells. Results showed that IC-2 decreased the proliferation ability of T24 cells in time-dependent and dose-dependent manners. Similarly, colony formation assay indicated that the higher concentration of IC-2 significantly decreased numbers of the colonies and the higher concentration of IC-2 significantly promoted the apoptosis of T24 cells. Therefore, our experiments and results strongly support the conclusion that IC-2 significantly inhibits bladder cancer cell proliferation and aggravates the apoptosis in a dose-dependent manner. Confirming the tumor-inhibition effect of IC-2 on bladder cancer may provide an important new therapeutic strategy for bladder cancer.

The molecular mechanisms of cancer are very complex, involving multiple genes, multiple factors and multiple stages [23]. Although the coordinated regulation of the genetic and external environments plays an important role in tumorigenesis, signal transduction pathways also act as a vital regulators [24]. In the normal cellular environment, Wnt signaling pathways are not activated, but they are activated in tumorigenesis. There are 2 types of Wnt/β-catenin signaling pathways: canonical and non-canonical branches. The canonical Wnt signaling is mediated by β-catenin and activates the TCF/LEF family of transcription factors, while the non-canonical Wnt/Ca²⁺ and Wnt/PCP pathways are independent of β-catenin [25].

The Wnt/β-catenin signaling pathway-related proteins β-catenin, Cyclin D1, and TCF4 were assessed by Western blot analysis. Results showed that the high concentration of IC-2 (2 μM) decreased the expression levels, suggesting that IC-2 inhibits the Wnt/β-catenin signaling pathway. Moreover, immunofluorescence assay showed that β-catenin moved and located in cytoplasm when treated with IC-2. In vivo, Western blot and immunohistochemistry assay showed that expression of β-catenin protein was decreased mice treated with IC-2 (5 mg/kg) and the tumor volume was also reduced, suggesting that IC-2 inhibits bladder cancer in vivo. InCRC cells, IC-2 reduced Wnt/β-catenin transcriptional activity and decreased the expression levels of cancer stem cell marker proteins [26].

Conclusions

We investigated and validated the function of novel small molecular inhibitor targeting Wnt pathway in bladder cancer cells, suggesting the valuable inhibition of bladder cancer tumorigenesis and providing a novel therapeutic strategy for bladder cancer.

Conflict of interest

None.

References:

1. John BA, Said N: Insights from animal models of bladder cancer: Recent advances, challenges, and opportunities. Oncotarget, 2017; 8: 57766–81
2. Cheng HP, Liu Q, Li Y et al: The inhibitory effect of PDIA6 downregulation on bladder cancer cell proliferation and invasion. Oncol Res, 2017; 25: 587–93
3. Chen Y, Zhang S, Zhao R et al: Upregulated miR-9-3p promotes cell growth and inhibits apoptosis in medulillary thyroid carcinoma by targeting BLCAP. Oncol Res, 2017; 25: 1215–22
4. Uihleg A, Strauss A, Seif Amir Hosseini A et al: Gender-specific differences in recurrence of non-muscle-invasive bladder cancer: A systematic review and meta-analysis. Eur Urol Focus, 2017; 6: 45–54
5. Wang H, Zou L, Ma K et al: Cell-specific mechanisms of TMEM16A Ca²⁺-activated chloride channel in cancer. Mol Cancer, 2017; 16: 152
6. Hussain M, Xu C, Lu M et al: Wnt/beta-catenin signaling links embryonic lung development and asthmatic airway remodeling. Biochimie, 2017; 124: 11–21
7. Slade L, Pulinikunnal T: The MITF/TFE family of transcription factors: Master regulators of organelle signalling, metabolism and stress adaptation. Mol Cancer Res, 2017; 65: 66–74
8. Cheng Z, Yuan X, Qu Y et al: Bruceine D inhibits hepatocellular carcinoma growth by targeting beta-catenin/jagged1 pathways. Cancer Lett, 2017; 403: 195–205

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
9. Chen F, Xiong W, Dou K, Ran Q: Knockdown of FOXK1 suppresses proliferation, migration, and invasion in prostate cancer cells. Oncol Res, 2017; 25: 1261–67

10. Deng X, Hamamoto R, Vougjouklakis T et al: Critical roles of SMYD2-mediated beta-catenin methylation for nuclear translocation and activation of Wnt signaling. Oncotarget, 2017; 8: 55837–47

11. Lin J, Tan X, Qiu L et al: Long noncoding RNA BC032913 as a novel therapeutic target for colorectal cancer that suppresses metastasis by upregulating TIMP3. Mol Ther Nucleic Acids, 2017; 8: 469–81

12. Santiago L, Daniels G, Wang D et al: Wnt signaling pathway protein LEF1 in cancer, as a biomarker for prognosis and a target for treatment. Am J Cancer Res, 2017; 7: 1389–406

13. Kishimoto Y, Ohkawara B, Sakai T et al: Wnt/beta-catenin signaling suppresses expressions of Socs, Mxcs, and Trmmd in tendon-derived cells. PLoS One, 2017; 12(7): e0182051

14. Wang Y, Zhao M, Liu J et al: miRNA-125b regulates apoptosis of human non-small cell lung cancer via the PI3K/Akt/GSK3beta signaling pathway. PLoS One, 2017; 38: 1715–23

15. Huang J, Guo L: Knockdown of SOX9 inhibits the proliferation, invasion, and EMT in thyroid cancer cells. Oncol Res, 2017; 25: 167–76

16. Li S, Zhang Y, Yang B: YEATS domain containing 4 promotes gastric cancer cell proliferation and mediates tumor progression via activating the Wnt/beta-catenin signaling pathway. Oncol Res, 2017; 6: 54–64

17. Waack U, Johnson TL, Chedid K et al: Targeting the type II secretion system: Development, optimization, and validation of a high-throughput screen for the identification of small molecule inhibitors. Front Cell Infect Microbiol, 2017; 7: 380

18. Jia D, Li L, Andrew S et al: An autocrine inflammatory forward-feedback loop after chemotherapy withdrawal facilitates the repopulation of drug-resistant breast cancer cells. Cell Death Dis, 2017; 8: e2932

19. Su N, Wang P, Li Y: Role of Wnt/beta-catenin pathway in inducing autophagy and apoptosis in multiple myeloma cells. Oncol Lett, 2016; 12: 4623–29

20. Hochman G, Halevi-Tobias K, Kogan Y, Agur Z: Extracellular inhibitors can attenuate tumorigenic Wnt pathway activity in adenomatous polyposis coli mutants: Predictions of a validated mathematical model. PLoS One, 2017; 12: e0179888

21. Seto K, Sakabe T, Itaba N et al: A novel small-molecule WNT inhibitor, IC-2, has the potential to suppress liver cancer stem cells. Anticancer Res, 2017; 37: 3569–79

22. Chen Z, Zhou L, Wang L et al: HBO1 promotes cell proliferation in bladder cancer via activation of Wnt/beta-catenin signaling. Mol Carcinog, 2018; 57: 12–21

23. Song Y, Li ZX, Liu X et al: The Wnt/beta-catenin and PI3K/Akt signaling pathways promote EMT in gastric cancer by epigenetic regulation via H3 lysine 27 acetylation. Tumour Biol, 2017; 39: 617–24

24. Zhou Y, Wang T, Hamilton JL, Chen D: Wnt/beta-catenin signaling in osteoarthritis and in other forms of arthritis. Curr Rheumatol Rep, 2017; 19: 53

25. Katoh M: Molecular genetics and targeted therapy of WNT-related human diseases (review). Int J Mol Med, 2017; 40: 587–606

26. Urushibara S, Tsubota T, Asai R et al: WNT/beta-catenin signaling inhibitor IC-2 suppresses sphere formation and sensitizes colorectal cancer cells to 5-fluorouracil. Anticancer Res, 2017; 37: 4085–91